Today's Date: June 12, 2024
“Golden Eight” Collection of Signed Michael Phelps Paintings Unveiled for the First Time Ahead of 2024 Summer Olympi   •   Parents as Teachers Receives $1.04 Million Grant from Bezos Family Foundation to Advance Life-Saving Maternal Health Initiative   •   United Teams Up with Chicago Bears to Support Special Olympics   •   Skyway Capital Markets, LLC Advises on the Sale of Aqua ChemPacs, LLC   •   Matthew Carnes, S.J., Named Vice President for Mission and Ministry at Santa Clara University   •   Sandbox VR Opens First Florida Location June 27 in the Grand Central District   •   PCI to Open State-of-the-Art Presort Mailing Facility in Indianapolis, Generating Nearly 100 Jobs   •   SBS Entertainment, La Musica and Mega 96.3FM's Summer Spotlight Series is back for its second year featuring live music performa   •   GREEN BAY INTEGRATIVE HEALTH LAUNCHES CUTTING-EDGE PROCEDURES FOR TIGHTENING/TONING MUSCLES WITHOUT PAIN OR DOWNTIME   •   Minister Sudds provides an update on Canada's progress on the 2030 Agenda for Sustainable Development   •   Church of the Highlands to Host “Cokes on the Lawn” After Monthly First Wednesday Service   •   THE JIM HENSON COMPANY IS TEAMING UP WITH THE OPERATING ROOM TO DEVELOP CG ANIMATED SERIES, ADRENALINE LEMMINGS   •   House Speaker to Host 3rd Annual Juneteenth Celebration   •   Inherited genetic factors may predict the pattern of X chromosome loss in older women   •   The Benefits Are On The Balance Sheet: Corporate America Must Stand By DEI And Chief Diversity Officers   •   University of Louisville Study Outlines Humana’s Economic and Community Impact on Kentucky   •   Statement by The National Council for Incarcerated and Formerly Incarcerated Women and Girls on Hunter Biden's Conviction   •   Reading Horizons Discovery® Earns Prestigious ‘All-Green’ Rating from EdReports   •   Church of the Highlands Hosted Their Annual Impact Golf Tournament to Benefit Local Organizations   •   Global Brain and Vision Research Nonprofit to Host Inaugural Concert for Cures Celebrating Science
Bookmark and Share

Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With

SAN FRANCISCO , May 22 /Businesswire/ - Today, Exavir Therapeutics announced that the company has entered into a settlement and license agreement with ViiV Healthcare for ultra-long-acting HIV compounds. As part of the agreement, Exavir will receive an upfront and milestone payments, as well as low-to-mid single digit royalties on future sales.

Exavir Therapeutics is focused on discovering and developing ultra-long-acting therapeutics with best-in-class product profiles. The company uses its proprietary prodrug and formulation technology to develop novel extended half-life therapeutics with potential for dosing as infrequent as once-every-six-months or even once-a-year.

“We are excited to reach an agreement with the scientific and market leader in long-acting injectables for HIV. We look forward to the continued success of ViiV Healthcare in their efforts to discover and develop more convenient and effective therapies for people living with HIV or at risk of acquiring HIV,” said Alborz Yazdi, co-founder and CEO of Exavir.

STORY TAGS: United States, North America, California, Contract/Agreement, Product/Service, White House/Federal Government, AIDS, Public Policy/Government, Health, Infectious Diseases, Pharmaceutical, Biotechnology,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News